IFNG and neoplasm: An intriguing phenomenon is that the loss of IFN-γ signaling (e.g., due to mutations in the JAK1 gene) leads to the inability to induce MHC class II expression on tumor cells, thus preventing their recognition and elimination by CD4+ CTLs.